Novo Nordisk A/S (CPH:NOVO.B)
Denmark
· Delayed Price · Currency is DKK 351.50
+3.00 (0.86%)
Sep 29, 2025, 4:59 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Victoza | 5.48B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Victoza Growth | -62.53% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Blood Disorders | 12.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Blood Disorders Growth | 6.53% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Endocrine Disorders | 4.99B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Endocrine Disorders Growth | 61.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Rare Disease | 1.51B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Rare Disease Growth | -0.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Diabetes Care | 2.12B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Diabetes Care Growth | -4.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Saxenda | 6.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Saxenda Growth | -39.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Long-Acting Insulin | 19.10B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Long-Acting Insulin Growth | 9.98% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Premix Insulin | 10.79B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Premix Insulin Growth | 11.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Fast-Acting Insulin | 18.52B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Fast-Acting Insulin Growth | 21.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Human Insulin | 6.97B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Human Insulin Growth | -6.28% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Ozempic | 120.34B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Ozempic Growth | 15.83% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rybelsus | 23.30B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rybelsus Growth | 11.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Wegovy | 58.21B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Wegovy Growth | 83.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Other | 11.54B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes & Obesity Care Operating Profit | 127.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diabetes & Obesity Care Operating Profit Growth | 26.80% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Disease Operating Profit | 620.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Disease Operating Profit Growth | 317.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 11.54B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 11.54B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| US Revenue | 167.40B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Revenue Growth | 21.13% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EUCAN | 57.55B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EUCAN Growth | 19.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets | 29.52B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Growth | 21.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC | 17.44B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Growth | 33.96% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | 18.50B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | 9.95% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue (Pre-FY2024 Reporting) | 18.50B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue (Pre-FY2024 Reporting) Growth | 9.95% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Revenue (Pre-FY2024 Reporting) | 167.40B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Revenue (Pre-FY2024 Reporting) Growth | 21.13% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other North American Operations (NAO) | 10.77B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other North American Operations (NAO) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA | 60.40B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World | 33.33B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|